Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and ...

Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating KYZATREX® (testosterone undecanoate) CIII capsules ...

The following information was released by the National Sleep Foundation:. Brian Clark is a writer and educator based in Los Angeles. His articles have appeared in The Austin Chronicle, Movieline and ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Secondary endpoints of the trial include changes in body weight and fasting blood glucose. Credit: superbeststock / Shutterstock.com. Ascletis Pharma has received investigational new drug (IND) ...

Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral GLP-1 race. The Chinese biotech evaluated three different once-daily doses of its oral ...

CPAP machines help people with sleep apnea breathe better by using a mask that delivers pressurized air. EPAP devices use your own breathing to keep airways open without needing a machine. Oral ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults receiving once-weekly 1.2 mg MET-097 lost 12.5% ...

Background: Sacubitril/Valsartan (S/V) benefits patients with heart failure with reduced ejection fraction (HFrEF), but its tolerability and clinical outcomes across age groups, especially the elderly ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images Preventing ...